耐药性 baumannii:死亡率,新兴的治疗方法,以及未来的药理学目标,为世卫组织优先病原体
Vineet Dubey1, Nada Reza1, William Hope1
1Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
杆菌感染是导致死亡的主要原因,特别是在危急病患者中. 本综述探讨了耐药性机制,并强调迫切需要针对这些多耐药和广泛耐药菌株的新疗法.
科学领域:
- 微生物学 微生物学
- 传染性疾病 传染性疾病
- 遗传学 遗传学 是一个
背景情况:
- 宝曼尼菌 (Acinetobacter baumannii) 是一个严重的全球健康威胁,导致重症患者的高死亡率.
- 其高度可塑性基因组促进了多药耐药 (MDR) 和广泛耐药 (XDR) 菌株的快速出现.
- 现有的治疗方法往往被细菌不断发展的耐药性所超越,导致高失败率.
研究的目的:
- 从2004年到2024年,系统地审查有关Acinetobacter baumannii耐药机制的文献.
- 为了突出与XDR和耐卡巴胺的A. baumannii (CRAB) 感染相关的死亡率.
- 讨论新兴的可用药物目标和下一代疗法的挑战.
主要方法:
- 2004年至2024年间发表的研究的系统文献综述.
- 对A. baumannii对传统和新型抗生素的耐药性机制的全面研究.
- 分析新出现的治疗目标和发展挑战.
主要成果:
- XDR和CRAB菌株与惊人的高死亡率有关.
- A. baumannii采用多种不同的分子机制来抵抗广泛的抗生素.
- 由于耐药性的快速演变,治疗的有效性经常受到损害.
结论:
- 了解A. baumannii的分子防御对于开发创新疗法至关重要.
- 迫切需要新的治疗策略来对抗不断升级的感染.
- 解决开发新可药物标的挑战对于未来的治疗计划至关重要.
更多相关视频
07:41Author Spotlight: A Comprehensive Protocol for Acinetobacter Biofilm Quantification, Assessment, and Visualization
Published on: August 4, 2023
09:29In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging
Published on: April 28, 2017
相关概念视频
Development of Antibiotic Resistance
Acute Pyelonephritis II: Diagnostic Studies and Management
Gene Regulation in Microbial Communities: Quorum Sensing
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Antimicrobial Effectiveness
